STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
drugs-5

Weight-Loss Battle Heats Up: GLP-1 Pills Could Challenge Novo Nordisk and Eli Lilly’s Dominance

byLiliana Vida
September 18, 2024
in Biotechnology, Large-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

As new GLP-1 oral pills enter the market, competition rises to challenge established injectables, sparking hope and concern over side effects

The weight-loss industry is gearing up for a seismic shift as companies race to introduce GLP-1 pills, potentially disrupting the dominance of injectable drugs led by Novo Nordisk (NVO) and Eli Lilly (LLY). With promising early data emerging from key players like Roche, Novo (NVO), and Pfizer (PFE), the market is abuzz with speculation on whether patients will prefer a daily pill over weekly or monthly injections.

While injectables like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro have revolutionized obesity treatment with remarkable results, new oral versions of GLP-1 medications are showing potential to replicate — and in some cases, surpass — the efficacy of injectables. However, the question remains: Will these pills gain widespread acceptance, and can they overcome the common side effects that continue to plague GLP-1 treatments?

Roche’s Phase 1 Trial Results: Promising Yet Concerning

Last week, Roche released early Phase 1 clinical trial data for its oral GLP-1 pill, which demonstrated a 6.1% weight loss over four weeks. While this may sound promising, experts and investors remain cautious. The study’s sample size was small, consisting of only 12 patients, which is standard for early-stage trials but not enough to draw definitive conclusions. Moreover, the results align with similar weight-loss figures seen in other oral GLP-1 contenders, including those from Pfizer, Novo, and Lilly.

Roche’s data placed the company among the key players vying for a slice of the oral weight-loss drug market. However, investors were quick to react to concerns over side effects, leading to a 5.4% decline in Roche’s stock price last week. Nausea, vomiting, and dizziness — common side effects for both injectable and oral GLP-1 medications — remain a significant issue, and Roche’s drug was no exception.

Despite this, some analysts believe the side effects may improve as the drug advances to later stages of testing. Etzer Darout, an analyst at BMO Capital Markets, explained that the rapid titration of doses in early trials often leads to more pronounced side effects. “We expect tolerability profiles to improve,” Darout said, suggesting that real-world use might reveal a more favorable balance between efficacy and side effects.

Lilly Sets the Benchmark with Orforglipron

Eli Lilly’s oral GLP-1 candidate, orforglipron, has set the benchmark for other contenders in the field. In its Phase 2 trials, orforglipron demonstrated a weight loss of up to 14.7% over 36 weeks, making it the frontrunner among oral options. This high level of efficacy has bolstered investor confidence in Lilly’s ability to maintain its market dominance as the leading provider of obesity treatments.

JPMorgan analyst Chris Schott noted that while there are several new entrants to the market, many lack differentiation from established players like Novo Nordisk and Lilly. Schott expressed skepticism about Roche’s potential to compete effectively, particularly given the side effect profile and its timeline for market entry, which could be as late as 2029-2031, years behind orforglipron’s expected availability.

Novo Nordisk and Terns Pharmaceuticals Add to the Competition

Novo Nordisk, a leader in the injectable GLP-1 space with its drug Wegovy, has also entered the race for oral treatments. Recent data from Novo revealed that its oral candidate led to 13.1% weight loss after just 12 weeks, outperforming Wegovy’s early results, which showed 6% weight loss in the same time frame. This could position Novo to maintain its dominance even as the market shifts toward pills over injections.

Another player, Terns Pharmaceuticals, also released early data showing a 4.9% weight loss over four weeks for its oral GLP-1 candidate. While Terns is further behind in the race, the company’s efforts to move into Phase 2 trials next year add to the expanding list of options for doctors and patients.

Dr. Michael Weintraub, an endocrinologist at NYU Langone Health, emphasized the importance of having multiple treatment options for obesity. “No single patient responds the same way,” Weintraub explained. “The more options, the better,” especially as the industry seeks to address related health conditions like heart disease and liver disease, which are often associated with obesity.

A Crowded Market, but Room for Growth

As more pharmaceutical companies enter the field with similar products, questions arise about how new entrants can differentiate themselves from the market leaders. While efficacy is critical, a key differentiator may lie in reducing the unpleasant side effects that patients currently experience with both injectable and oral GLP-1 drugs.

Despite the market being flooded with new contenders, the demand for effective weight-loss treatments continues to grow, and many experts believe that competition will ultimately benefit patients. “We can’t yet predict which medication will work for a particular patient,” Dr. Weintraub pointed out, underscoring the need for a range of treatment options.

As trials progress and more data becomes available, the weight-loss industry is poised for a shakeup. Whether patients prefer daily pills or stick with injectables, the coming years will likely see significant advances in how obesity is treated, with companies like Novo Nordisk, Eli Lilly, Roche, and Pfizer leading the charge.

You might like this article:Intuitive Machines Secures $4.82 Billion NASA Contract to Lead Lunar Communication and Navigation

Tags: BreakingGLP-1GrowthMoversNewsStock Market
Previous Post

Intuitive Machines Secures $4.82 Billion NASA Contract to Lead Lunar Communication and Navigation

Next Post

BlackRock and Microsoft Join Forces for $100 Billion AI Infrastructure Investment

Related Posts

virtual makeup

Ulta Beauty Posts Strong Q2 Results with 9.3% Sales Growth

byLuca Blaumann
August 28, 2025
0

Acquisition of Space NK and Robust Consumer Demand Drive Performance Ulta Beauty (ULTA) delivered a strong second quarter in fiscal...

tesla-2

Tesla’s European Sales Slide Deepens Amid Rising Competition

byLuca Blaumann
August 28, 2025
0

Registrations plunge over 40% in July as rivals gain ground and Musk faces reputational challenges Tesla’s (TSLA) struggles in Europe...

Cracker Barrel Reverts to Classic Logo After Backlash and Trump Pressure

byLiliana Vida
August 27, 2025
0

Shares Jump as Company Abandons Minimalist Redesign Cracker Barrel (CBRL) has scrapped its recent logo redesign after customer backlash and...

Next Post

BlackRock and Microsoft Join Forces for $100 Billion AI Infrastructure Investment

Latest News

Professional Diversity Network Partners with OOKC Group to Build Web3.0 Banking Platform

Ulta Beauty Posts Strong Q2 Results with 9.3% Sales Growth

Tesla’s European Sales Slide Deepens Amid Rising Competition

Nvidia Surpasses Earnings Expectations as AI Demand Fuels Growth

Cracker Barrel Reverts to Classic Logo After Backlash and Trump Pressure

Based on Your Interest

Large-Cap

U.S. Secures 10% Stake in Intel Amid Tumultuous Turnaround

August 25, 2025
Large-Cap

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

August 21, 2025
Large-Cap

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

August 20, 2025

Recommended

Mid-Cap

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

August 19, 2025
Large-Cap

Intel Shares Surge After $2 Billion SoftBank Investment

August 19, 2025
Bitcoin

Strategy Expands Bitcoin Holdings With $51 Million Purchase

August 18, 2025
Aerospace & Defense

Amphenol Expands Defense Portfolio With $1 Billion Trexon Acquisition

August 18, 2025
Insurance

Buffett Bet Sends UnitedHealth Shares Soaring

August 18, 2025
Stoxpo

Follow us on social media:

Highlights

  • Professional Diversity Network Partners with OOKC Group to Build Web3.0 Banking Platform
  • Ulta Beauty Posts Strong Q2 Results with 9.3% Sales Growth
  • Tesla’s European Sales Slide Deepens Amid Rising Competition
  • Nvidia Surpasses Earnings Expectations as AI Demand Fuels Growth
  • Cracker Barrel Reverts to Classic Logo After Backlash and Trump Pressure

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Professional Diversity Network Partners with OOKC Group to Build Web3.0 Banking Platform

August 29, 2025
virtual makeup

Ulta Beauty Posts Strong Q2 Results with 9.3% Sales Growth

August 28, 2025
tesla-2

Tesla’s European Sales Slide Deepens Amid Rising Competition

August 28, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?